These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 37306118)

  • 1. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
    Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
    J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.
    O'Halloran JA; Sahrmann J; Butler AM; Olsen MA; Powderly WG
    J Acquir Immune Defic Syndr; 2020 Aug; 84(4):396-399. PubMed ID: 32243280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.
    Benson C; Emond B; Lefebvre P; Lafeuille MH; Côté-Sergent A; Tandon N; Chow W; Dunn K
    J Manag Care Spec Pharm; 2020 Feb; 26(2):129-141. PubMed ID: 31747358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada.
    Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD
    Clin Infect Dis; 2021 Oct; 73(7):e1408-e1414. PubMed ID: 32780095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration.
    Rein SM; Lodi S; Logan RW; Touloumi G; Antoniadou A; Wittkop L; Bonnet F; van Sighem A; van der Valk M; Reiss P; Klein MB; Young J; Jarrin I; d'Arminio Monforte A; Tavelli A; Meyer L; Tran L; Gill MJ; Lang R; Surial B; Haas AD; Justice AC; Rentsch CT; Phillips A; Sabin CA; Miro JM; Trickey A; Ingle SM; Sterne JAC; Hernán MA;
    Lancet HIV; 2023 Nov; 10(11):e723-e732. PubMed ID: 37923486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
    Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
    Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors.
    Chen YW; Anderson D; Pericone CD; Donga P
    J Health Econ Outcomes Res; 2022; 9(1):1-10. PubMed ID: 35083364
    [No Abstract]   [Full Text] [Related]  

  • 9. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
    Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Assessment of Weight Change in People with HIV-1 After Initiating Integrase Strand Transfer Inhibitors or Protease Inhibitors.
    Chen YW; Hardy H; Pericone CD; Chow W
    J Health Econ Outcomes Res; 2020; 7(2):102-110. PubMed ID: 32766375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency Virus.
    O'Halloran JA; Sahrmann J; Parra-Rodriguez L; Vo DT; Butler AM; Olsen MA; Powderly WG
    Clin Infect Dis; 2022 Dec; 75(12):2060-2065. PubMed ID: 35521785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
    Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
    Trickey A; Zhang L; Gill MJ; Bonnet F; Burkholder G; Castagna A; Cavassini M; Cichon P; Crane H; Domingo P; Grabar S; Guest J; Obel N; Psichogiou M; Rava M; Reiss P; Rentsch CT; Riera M; Schuettfort G; Silverberg MJ; Smith C; Stecher M; Sterling TR; Ingle SM; Sabin CA; Sterne JAC
    Lancet HIV; 2022 Jun; 9(6):e404-e413. PubMed ID: 35659335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
    Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
    Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
    Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
    Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
    Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T
    J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan.
    Wang X; Schmerold L; Naito T
    J Infect Chemother; 2022 Nov; 28(11):1464-1470. PubMed ID: 35850403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.
    Donga P; Emond B; Rossi C; Bookhart BK; Lee J; Caron-Lapointe G; Wei F; Lafeuille MH
    Clinicoecon Outcomes Res; 2023; 15():579-591. PubMed ID: 37521004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.